CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 146 enrolled
Drug / intervention
Capecitabine 1650 mg/m^2/day +8 moredrug
Likely dose
Capecitabine 825 mg/m² orally twice daily (1650 mg/m²/day) 5 days/week during 6 weeks of pelvic radiation, with oxaliplatin 50 mg/m² IV days 1, 8, 15, 22, 29 and irinotecan 50 mg/m² IV days 1, 8, 22, 29; followed by adjuvant oxaliplatin 85 mg/m² IV, folinic acid 400 mg/m² IV, and 5-FU (bolus 400 mg/m² + infusion 2400 mg/m²) every 14 days for 9 cycles post-operativelyAI-extracted
Key inclusion· 5
  • Adenocarcinoma of the rectum at or below 12 cm from anal verge without distant metastases
  • Age ≥18 years
  • Potentially resectable disease by surgeon evaluation
  • Clinical stages T3 or T4 by endorectal ultrasound or physical exam
Key exclusion· 9
  • Any evidence of distant metastasis
  • Synchronous primary colon carcinomas except T1 lesions
  • Extension of malignant disease to the anal canal
  • Prior radiation therapy to the pelvis

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00081289
NCT00081289Phase 2Completed

Randomized Phase II Trial Of Neoadjuvant Combined Modality Therapy For Locally Advanced Rectal Cancer

Radiation Therapy Oncology Group·interventional·Posted Apr 8, 2004·Updated Feb 27, 2020

In Brief

A Phase 2 clinical trial evaluating Radiation Therapy, Capecitabine 1650 mg/m^2/day, and 6 other interventions for Colorectal Cancer. Completed, enrolled 146 participants across 5 sites.

Detailed Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Chemoradiotherapy (combining chemotherapy with radiation therapy) before surgery may shrink the tumor so that it can be removed. Giving chemotherapy after surgery may kill any remaining tumor cells. PURPOSE: This randomized phase II trial is studying two different regimens of neoadjuvant chemoradiotherapy and adjuvant chemotherapy and comparing how well they work in treating patients who are undergoing surgical resection for locally advanced rectal cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 8, 2004
Enrollment StartMar 1, 2004
Primary CompletionMay 1, 2011
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 22.2 years ago

Interventions

Radiation Therapyradiation

Pelvic radiation therapy given once daily 5 days a week for 6 weeks, 45 Gy in 25 fractions + boost of 5.4 Gy in 3 fractions for a total dose of 50.4 Gy.

Capecitabine 1650 mg/m^2/daydrug

825 mg/m\^2 q12 hours (1650 mg/m\^2/day) orally 5 days per week during radiotherapy.

Capecitabine 1200 mg/m^2/daydrug

600 mg/m\^2 q12 hours(1200 mg/m\^2/day) orally 5 days per week during radiotherapy.

Irinotecandrug

50mg/m\^2 IV over 1 hour on days 1, 8, 22, and 29

Oxaliplatindrug

50mg/m\^2 IV over 2 hours on days 1, 8, 15, 22, and 29

Surgeryprocedure

All patients will undergo surgery four to eight weeks following the completion of radiation therapy. The choice of procedure abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis is at the discretion of the surgeon.

Folinic Aciddrug

400 mg/m\^2 IV over 2 hours Day 1 (postoperatively) ,every 14 days, for nine 14-day cycles.

Fluorouracildrug

5-fluorouracil bolus 400 mg/m\^2 IV push Day 1 (postoperatively), every 14 days, for nine 14-day cycles. 5-fluorouracil infusion 2400 mg/m\^2 IV continuous infusion over 46 hours, beginning day 1, every 14 days, for nine 14-day cycles.

Oxaliplatindrug

85 mg/m\^2 IV over 2 hours Day 1 (postoperatively), every 14 days, for nine 14-day cycles.